Translational Cancer Research

Scope & Guideline

Empowering cancer research with open access insights.

Introduction

Welcome to the Translational Cancer Research information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Translational Cancer Research, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2218-676x
PublisherAME PUBLISHING COMPANY
Support Open AccessNo
CountryHong Kong
TypeJournal
Convergefrom 2012 to 2024
AbbreviationTRANSL CANCER RES / Transl. Cancer Res.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressFLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA

Aims and Scopes

Translational Cancer Research is dedicated to bridging the gap between basic cancer research and clinical applications, striving to improve patient outcomes through innovative research and methodologies.
  1. Molecular Mechanisms of Cancer:
    The journal focuses on the molecular and cellular mechanisms underlying cancer development and progression, including studies on gene expression, signaling pathways, and tumor microenvironment interactions.
  2. Biomarker Discovery and Validation:
    There is a strong emphasis on identifying and validating new biomarkers for cancer diagnosis, prognosis, and treatment response, utilizing bioinformatics, genomics, and proteomics approaches.
  3. Therapeutic Strategies:
    Research articles often explore novel therapeutic strategies, including targeted therapies, immunotherapies, and combination treatments, assessing their effectiveness and safety through clinical trials and preclinical studies.
  4. Clinical Research and Trials:
    The journal publishes findings from clinical studies aimed at improving treatment protocols and understanding patient responses, including retrospective analyses, meta-analyses, and randomized controlled trials.
  5. Translational Approaches:
    A unique contribution of the journal is its commitment to translational research, integrating laboratory findings with clinical practices to enhance therapeutic outcomes in cancer patients.
Recent trends within Translational Cancer Research indicate a shift towards several emerging themes that reflect the current landscape of cancer research and treatment strategies.
  1. Immunotherapy and Combination Treatments:
    There is a growing emphasis on the exploration of immunotherapy, particularly its combination with other treatment modalities, showcasing the potential for enhanced efficacy in cancer therapies.
  2. Bioinformatics and Computational Biology:
    The application of bioinformatics tools for data analysis, particularly in genomics and proteomics, is gaining traction as researchers seek to identify novel biomarkers and therapeutic targets.
  3. Cancer Microenvironment Studies:
    Research focusing on the tumor microenvironment, including immune cell interactions and extracellular matrix components, is increasingly relevant as it plays a crucial role in tumor progression and therapy resistance.
  4. Liquid Biopsies and Non-Invasive Diagnostics:
    The emergence of liquid biopsy techniques for cancer detection and monitoring is a significant trend, reflecting a shift towards less invasive diagnostic methods that provide real-time insights into tumor dynamics.
  5. Personalized Medicine Approaches:
    There is an increasing trend towards personalized medicine, with studies focusing on tailoring treatments based on individual genetic profiles and tumor characteristics to improve patient outcomes.

Declining or Waning

As the field of cancer research evolves, certain themes within Translational Cancer Research have shown a decline in frequency or prominence. This section highlights those waning scopes.
  1. Traditional Chemotherapy Studies:
    Research focused solely on traditional chemotherapy regimens without the integration of newer modalities such as immunotherapy or targeted therapy has decreased, reflecting a shift towards more innovative treatment approaches.
  2. Basic Science Studies without Clinical Relevance:
    There is a noticeable waning interest in basic science studies that do not directly translate to clinical applications or patient outcomes, as the focus shifts towards more applicable research.
  3. Single-Agent Drug Trials:
    The frequency of publications centered on single-agent drug trials has diminished, as combination therapies and personalized medicine strategies gain more attention in the quest for effective cancer treatments.

Similar Journals

CLINICAL & EXPERIMENTAL METASTASIS

Advancing Knowledge in Metastatic Disease
Publisher: SPRINGERISSN: 0262-0898Frequency: 6 issues/year

CLINICAL & EXPERIMENTAL METASTASIS is a highly regarded academic journal dedicated to the study of cancer metastasis, published by Springer. With an ISSN of 0262-0898 and an E-ISSN of 1573-7276, this journal serves as a pivotal resource for researchers and professionals dedicated to understanding the complexities of metastatic disease. Based in the Netherlands, it boasts an impressive impact factor, solidifying its position in two major quartiles: Q2 in Cancer Research and Q1 in both Medicine (Miscellaneous) and Oncology for 2023. The journal not only ranks among the top tier in Medicine Oncology—84th out of 404—but also excels in Biochemistry, Genetics and Molecular Biology in Cancer Research, ranking 75th out of 230. With coverage spanning from 1983 to 2024, CLINICAL & EXPERIMENTAL METASTASIS presents cutting-edge research, reviews, and clinical studies that drive the field forward. This journal is essential for anyone looking to deepen their understanding of cancer metastasis and its underlying mechanisms.

Molecular Cancer

Unlocking the secrets of cancer biology and treatment.
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

Discover Oncology

Exploring the frontiers of oncology and endocrinology.
Publisher: SPRINGERISSN: Frequency: 1 issue/year

Discover Oncology, published by SPRINGER, is an influential journal based in Germany that focuses on the latest advancements in the fields of oncology and endocrinology. With an evolving scope that spans critical research from 2021 to 2024, this journal aims to provide a platform for innovative ideas and research findings that can significantly impact clinical practices. Although it currently holds a Q3 ranking in several Cancer Research and Endocrine category quartiles, its commitment to open access ensures that relevant knowledge is available to a wider audience, facilitating the exchange of ideas among researchers, professionals, and students. As evidenced by its growing presence in various medical spheres, including a Q2 ranking in Endocrinology and Diabetes, the journal plays a crucial role in advancing multidisciplinary research that integrates oncology with broader biological and medical parameters. For those in the field, Discover Oncology serves as both a resource and a community hub, encouraging collaboration and exploration of emerging findings that can lead to novel therapeutic approaches.

OncoTargets and Therapy

Advancing cancer research for a healthier tomorrow.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6930Frequency: 1 issue/year

OncoTargets and Therapy is a prestigious, peer-reviewed journal dedicated to the rapid dissemination of research in the fields of oncology and pharmacology. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this journal has embraced the open access model, ensuring that critical cancer-related research is freely accessible to a global audience. With an impressive impact factor reflected by its Q2 ranking in both the Oncology and Pharmacology (medical) categories for 2023, as well as Scopus rankings placing it in the top 91st percentile in pharmacology and the 84th percentile in oncology, OncoTargets and Therapy stands out as a vital resource for researchers, clinicians, and students alike. The journal focuses on therapeutics, novel drug discoveries, and clinical trials, encouraging collaborative efforts to combat cancer effectively. By providing a platform for groundbreaking studies and comprehensive reviews, it plays a crucial role in advancing knowledge and practice in these critical areas of medical science.

BRITISH JOURNAL OF CANCER

Transforming Cancer Care with Cutting-Edge Discoveries.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Cancers

Advancing cancer research for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

NATURE REVIEWS CANCER

Navigating the Complexities of Cancer Science
Publisher: NATURE PORTFOLIOISSN: 1474-175XFrequency: 12 issues/year

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

Journal of Cancer

Championing open access to vital cancer research.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

MOLECULAR CANCER RESEARCH

Exploring Breakthroughs in Cancer Biology
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

ONCOLOGY RESEARCH

Fostering Excellence in Oncology Research and Practice
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.